Vision and Philosophy

Medicine and ethics are inseparable. Since Hippocrates, this has been a consensus among responsible physicians in all fields. A consensus that is becoming more important than ever in the light of the revolutionary possibilities of future diagnostic and therapeutic procedures.

TICEBA - Company - Vision and Philosophy

Vision

We offer our clients a unique, valuable preventive health care measure for the future, while taking into account the latest international findings from science and research and meeting the highest international standards.


Philosophy

We offer diverse fields of activity to our staff, in which they are able to develop freely. Through open communication transparency and efficiency are to be cultivated. We thus cultivate a continuous development of our staff and are at the same time striving at a sustainable staff loyalty.

It is our first priority to fulfill our customers' wishes. We reach this target by way of open conversations, reliable consulting services and individual recommendations. Continuous development of our products and our product portfolio through well-founded research opens new chances and opportunities to our clients.

We are loyal and reliable towards our business partners. We strive towards continuous improvement through open, efficient and honest communication. The interests of both parties are to be taken into account and preserved.

Adhering to continuous quality as well as complying with regulations plays a decisive role for us. Only by diligent implementation of the set standards are we able to meet the enormous requirements of our products.


Ethics

"Keeping and restoring the health of my patients shall be the first and foremost command of my actions". This key sentence of the "Declaration of Geneva", which every physician solemnly attests to upon entering his profession, is the foundation of our company. We feel particularly committed to these ethical principles and have therefore established the target of generating access to the medical progress of the future to be expected for everyone even today.

News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter